Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics, Inc. (NASDAQ: ANGO) has announced that Jim Clemmer, President and CEO, along with Stephen Trowbridge, Executive VP and CFO, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 2:50 p.m. ET on January 14, 2021.
A live webcast will be available in the 'Investors' section of AngioDynamics' website, with a replay accessible after the event. AngioDynamics specializes in innovative, minimally invasive medical devices focused on vascular access, peripheral vascular disease, and oncology.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 23rd Annual Needham Virtual Growth Conference on January 11, 2021, at 1:15 p.m. ET. The presentation will be streamed live on the company's website, with a replay available afterward. AngioDynamics specializes in minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse range of products including ablation and vascular access systems.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for the second quarter of fiscal 2021 on January 7, 2021, before the market opens. A conference call to discuss these results will take place at 8:00 a.m. ET on the same day, with participation options available via phone and webcast. AngioDynamics specializes in innovative, minimally invasive medical devices for vascular access, oncology, and peripheral vascular disease, with a diverse range of products including ablation systems and drainage products.
AngioDynamics (NASDAQ: ANGO) reported its fiscal Q1 2021 results with net sales of $70.2 million, a 6.3% increase year-over-year. The company faced challenges from COVID-19, particularly in its Oncology segment, where net sales dropped 12.3% to $12.3 million. The Vascular Access segment saw strong growth of 21.4%, totaling $28.1 million. Gross margin declined to 50.9%, down 700 basis points year-over-year. A net loss of $4.3 million was reported, or $0.11 per share. Guidance for fiscal 2021 projects net sales between $278 million and $284 million.